CN106333869A - 一种具有美白祛斑作用的护肤品及其制备方法 - Google Patents
一种具有美白祛斑作用的护肤品及其制备方法 Download PDFInfo
- Publication number
- CN106333869A CN106333869A CN201610944379.0A CN201610944379A CN106333869A CN 106333869 A CN106333869 A CN 106333869A CN 201610944379 A CN201610944379 A CN 201610944379A CN 106333869 A CN106333869 A CN 106333869A
- Authority
- CN
- China
- Prior art keywords
- skin care
- care item
- whitening
- mass percentage
- percentage composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 80
- 230000000694 effects Effects 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 208000003351 Melanosis Diseases 0.000 title abstract description 8
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 34
- 230000008439 repair process Effects 0.000 claims abstract description 24
- RHYBFKMFHLPQPH-UHFFFAOYSA-N N-methylhydantoin Chemical compound CN1CC(=O)NC1=O RHYBFKMFHLPQPH-UHFFFAOYSA-N 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 60
- 239000002253 acid Substances 0.000 claims description 33
- 150000003949 imides Chemical class 0.000 claims description 32
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 19
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 11
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229940068041 phytic acid Drugs 0.000 claims description 11
- 235000002949 phytic acid Nutrition 0.000 claims description 11
- 239000000467 phytic acid Substances 0.000 claims description 11
- 229930182478 glucoside Natural products 0.000 claims description 10
- 150000008131 glucosides Chemical class 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- CNXJITYCNQNTBD-UHFFFAOYSA-L dipotassium;hexadecyl phosphate Chemical compound [K+].[K+].CCCCCCCCCCCCCCCCOP([O-])([O-])=O CNXJITYCNQNTBD-UHFFFAOYSA-L 0.000 claims description 9
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 7
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 7
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical group CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000002421 anti-septic effect Effects 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 230000000149 penetrating effect Effects 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 230000008719 thickening Effects 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 241000259759 Cassida nobilis Species 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 34
- 102000003425 Tyrosinase Human genes 0.000 abstract description 11
- 108060008724 Tyrosinase Proteins 0.000 abstract description 11
- 239000000047 product Substances 0.000 abstract description 11
- 238000012546 transfer Methods 0.000 abstract description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 5
- 239000001301 oxygen Substances 0.000 abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 abstract description 3
- 229940088597 hormone Drugs 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract 2
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 abstract 1
- 206010014970 Ephelides Diseases 0.000 abstract 1
- 208000028990 Skin injury Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000012466 permeate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 62
- 230000001629 suppression Effects 0.000 description 25
- 239000006071 cream Substances 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000003064 anti-oxidating effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- AMUTYVGRCVFCCD-UHFFFAOYSA-N 5,6-diaminopyridine-3-carboxylic acid Chemical compound NC1=CC(C(O)=O)=CN=C1N AMUTYVGRCVFCCD-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 5
- 229960004705 kojic acid Drugs 0.000 description 5
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 235000014593 oils and fats Nutrition 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 229940051841 polyoxyethylene ether Drugs 0.000 description 5
- 229920000056 polyoxyethylene ether Polymers 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 229940016667 resveratrol Drugs 0.000 description 5
- 235000021283 resveratrol Nutrition 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 210000002780 melanosome Anatomy 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000037307 sensitive skin Effects 0.000 description 4
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036564 melanin content Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- -1 acyl group ortho-aminobenzoic acid Compound Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012490 blank solution Substances 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229940035423 ethyl ether Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 108010070503 PAR-2 Receptor Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000018402 Protease-activated receptor 2 Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 210000000835 hypertrophic cicatrix Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N o-aminobenzenecarboxylic acid Natural products NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/445—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有美白祛斑作用的护肤品,所述护肤品包括苯乙基间苯二酚、1‑甲基乙内酰脲‑2‑酰亚胺、抗敏修复肽。本发明所述护肤品,不仅能够有效地渗透到皮肤的基底层,而且能够有效地竞争性抑制酪氨酸酶的活性,同时可抑制黑色素的转移,高效清除氧自由基,防止黑色素的产生,同时还原分解已有的黑色素,活化细胞,淡化面部斑点,同时修复由于激素等化学成分对皮肤造成的损伤,从而达到全面快速、标本兼治的效果,使得皮肤美白、滋润保湿、光泽细腻。同时,本发明还公开了所述具有美白祛斑作用的护肤品的制备方法。
Description
技术领域
本发明涉及护肤品技术领域,尤其是一种具有美白祛斑作用的护肤品及其制备方法。
背景技术
美白一直是亚洲女性所追求的,而随着人民生活水平和审美标准的提高,白皙和洁润的肌肤更是越来越被推崇。黑色素的分布和数量决定皮肤的颜色,它又由两大因素决定(1)遗传基因:基因决定皮肤黑素细胞的分布和数量等。例如黑色人种黑素细胞的数量是白人的100多倍;(2)非遗传基因:一些非遗传因素导致人体内因环境变化引发的黑色素沉淀,例如内分泌失调、代谢紊乱、疾病损伤、紫外线辐射、皮肤炎症、体内氧化与抗氧化平衡失调、饮食富含铜、铁、锌等金属的食物等。其中最常见的是紫外线辐射,紫外线辐射又可以引发炎症,加重对皮肤的损伤。
目前,美白原料的开发越来越重视其抗氧化能力。抗氧化剂可以从三个方面发挥美白效果:(1)捕获自由基,从源头上抑制紫外线辐射等引起酪氨酸酶基因表达;(2)抑制活性氧对酪氨酸酶的供氧作用,抑制多巴和多巴醌的形成;(3)抗氧化剂直接还原黑色素成无色物质。另外,许多抗氧化美白原料同时具有络合酪氨酸酶活性部位铜离子Cu2+的能力,原料本身也可能为酪氨酸酶底物的竞争性抑制剂,例如,根皮素,氧化白藜芦醇、姜黄素等。
长期以来,美白祛斑是大多数爱美的女性所追求的目标。而美容界几乎把含汞、氢醌的制剂当作唯一有效的美白祛斑产品。含违禁成分过万倍的汞及其化合物祛斑一周见效,毒性积聚致使无数消费者面部细胞坏死,留下不可治愈的青斑;氢醌的限用量为0.02%,而超过限用量上百倍的氢醌才能有明显效果,但若长期使用会在脸上留下不正常的白块。
有鉴于此,确有必要提供一种安全、有效的美白祛斑护肤品,其能有效解决色素沉着引发的肌肤问题,并具有美白效果,使用方便,效果显著。
发明内容
基于此,本发明的目的在于克服上述现有技术的不足之处而提供一种具有美白祛斑作用的护肤品。
为实现上述目的,本发明所采取的技术方案为:一种具有美白祛斑作用的护肤品,所述护肤品包括苯乙基间苯二酚、1-甲基乙内酰脲-2-酰亚胺、抗敏修复肽。
黑色素既是紫外吸收剂,又是活性氧清除剂,是皮肤自我防护物质,能够使皮肤免于紫外线辐射等产生的伤害,也就说黑色素是一种体内的抗氧化剂。所以摄入外源的抗氧化剂可以作为黑色素的竞争性抗氧化剂,捕获自由基,抑制酪氨酸酶活性,从而抑制黑色素生成,达到美白的效果。
本发明所述护肤品中苯乙基间苯二酚为一种紫外光吸收剂,能够竞争性抑制酪氨酸酶活性,主要抑制黑色素B16细胞,抑制酪氨酸酶活性的效果为β-熊果苷100倍,为曲酸的22倍,甚至好于2%氢醌的抑制黑色素效果,而且还可以清除自由基,抗炎症。
1-甲基乙内酰脲-2-酰亚胺(SL-C 280)为天然的氨基酸衍生物,在哺乳动物细胞内普遍存在,是一种无细胞毒性的、长期使用无副作用的温和美白祛斑原料,是强大的美白剂,同时具有抑制酪氨酸酶活性、抑制黑素小体转移的双重功能,美白效果媲美曲酸。1-甲基乙内酰脲-2-酰亚胺是竞争性抑制剂,非还原性抑制,结构稳定,不易变色。针对黑色素生成的不同阶段,有以下三大美白机理:
(1)抑制酪氨酸酶生成。抑制黑色素细胞中酪氨酸酶基因表达,即抑制酪氨酸酶的合成,使酪氨酸酶的含量下降,即可减少黑色素的形成,如维生素A;
(2)抑制酪氨酸酶活性。酪氨酸酶是黑色素形成的重要限速酶,能够催化酪氨酸氧化,逐步形成多巴和多巴醌,多巴醌在经过进一步重排、氧化、聚合形成黑色素;酪氨酸酶活性抑制机理可细分为:竞争性抑制、还原性抑制和络合性抑制。市场上多数美白原料多属于还原性抑制剂,容易变色,如维生素C及其衍生物,熊果苷;
(3)抑制黑素小体的转移。黑色素由皮肤表皮层的黑色素细胞合成,通过突触转移到角质形成细胞,角质形成细胞中的黑色素含量越多,表现为皮肤颜色越沉。抑制黑色素转移到角质形成细胞,即可降低角质形成细胞黑色素含量,提亮肤色。
抗敏修复肽是一种复合肽,主要是由乙酰六肽-46和二氢燕麦酰基邻氨基苯甲酸复配而成,所述抗敏修复肽可从市场直接购买,例如购自广州欣浪生化有限公司,商品名:ASR-39。抗敏修复肽中不同机理的胜肽协同增效,具有强大的抗敏、消炎、修复和皮肤重塑,舒缓敏感肌肤作用。所述抗敏修复肽很大程度减少皮肤过敏、刺痛现象,同时促进皮肤受损愈合和修复,提高皮肤屏障保护功能。特别适合于抗炎修复配方和敏感肌肤。
(1)消炎抗敏
抗敏修复肽中的胜肽能够有效抑制PAR-2(蛋白酶激活受体-2)的活性,同时复配燕麦提取物,降低促炎介质IL-6、IL-8、组胺、SP、CGRP的释放。
(2)重塑皮肤
抗敏修复肽促进板层小体(LB)、弹性蛋白、胶原蛋白合成,提高持水蛋白多糖含量;促进皮肤血液微循环;减少TGF-β-1和TNF-α含量,防止皮肤愈合过程中的增生性瘢痕的形成。
(3)舒缓敏感肌肤
抗敏修复肽具有的抗炎、屏障修复功效,进一步降低炎症介质对外周神经的刺激,减少神经生长因子(NGF)的产生,降低神经高敏性,使敏感肌肤得到舒缓和改善,同时配合抗组胺成分,减少原料引起的皮肤发红、发痒现象。
优选地,所述苯乙基间苯二酚在所述护肤品中的质量百分含量为0.05~2%,所述1-甲基乙内酰脲-2-酰亚胺在所述护肤品中的质量百分含量为0.5~5%,所述抗敏修复肽在所述护肤品中的质量百分含量为0.5~5%。
更优选地,所述苯乙基间苯二酚在所述护肤品中的质量百分含量为0.1~1%,所述1-甲基乙内酰脲-2-酰亚胺在所述护肤品中的质量百分含量为1~3%,所述抗敏修复肽在所述护肤品中的质量百分含量为2~4%。
更优选地,所述苯乙基间苯二酚在所述护肤品中的质量百分含量为0.5%,所述1-甲基乙内酰脲-2-酰亚胺在所述护肤品中的质量百分含量为2%,所述抗敏修复肽在所述护肤品中的质量百分含量为3%。
本申请发明人经过大量尝试发现,由于苯乙基间苯二酚有轻微的刺激、刺痛感,加入抗敏修复剂可以有效解决刺痛感,降低过敏率,上述含量的三种物质共同作用,可以达到更好的美白祛斑效果。
优选地,所述护肤品还包含葛根素,所述葛根素在所述护肤品中的质量百分含量为0.5~1.5%。由于苯乙基间苯二酚易变色,所述葛根素为调色剂。
优选地,所述护肤品还包含植酸,所述植酸在所述护肤品中的质量百分含量为0.1~0.5%。植酸作为螯合剂、抗氧化剂等,植酸本身就是对人体有益的营养品,植酸在人体内水解产物为肌醇和磷脂,前者具有抗衰老作用,后者是人体细胞重要组成部分。
优选地,所述护肤品还包含表面活性剂,所述表面活性剂包含十六烷基磷酸酯钾盐、鲸蜡硬脂基葡糖苷中的至少一种;
所述表面活性剂包含十六烷基磷酸酯钾盐时,所述十六烷基磷酸酯钾盐在所述护肤品中的质量百分含量为0.5~1.5%;
所述表面活性剂包含鲸蜡硬脂基葡糖苷时,所述鲸蜡硬脂基葡糖苷在所述护肤品中的质量百分含量为1~3%。
优选地,所述护肤品还包含抗氧化剂、润湿剂、促渗剂、增稠稳定剂、杀菌防腐剂、乳化剂中的至少一种。所述抗氧化剂、润湿剂、促渗剂、增稠稳定剂、杀菌防腐剂、乳化剂的用量没有特别限定,其用量为本领域技术人员根据现有技术及实际需求即可得到。
更优选地,所述抗氧化剂为维生素E、焦亚硫酸钠中的至少一种,所述润湿剂为肉豆蔻酸异丙酯,所述促渗剂为氮酮,所述增稠稳定剂为汉生胶,所述杀菌防腐剂为尼伯金甲酯,所述乳化剂为硬脂酸甘油酯。
优选地,所述护肤品还包含去离子水、基质及护肤品领域可接受的辅料。
同时,本发明还提供了一种上述具有美白祛斑作用的护肤品的制备方法,所述方法包括如下步骤:
将除葛根素、抗敏修复肽、1-甲基乙内酰脲-2-酰亚胺以外的其他原料在去离子水中加热溶解到80~90℃,混合均匀,然后加入1-甲基乙内酰脲-2-酰亚胺混合均匀,再依次加入抗敏修复肽、葛根素混合均匀,即得所述具有美白祛斑作用的护肤品。
相对于现有技术,本发明的有益效果为:
本发明所述护肤品,以苯乙基间苯二酚、1-甲基乙内酰脲-2-酰亚胺、抗敏修复肽作为美白祛斑的主要成分,制得的具有美白祛斑作用的护肤品不仅能够有效地渗透到皮肤的基底层,而且能够有效地竞争性抑制酪氨酸酶的活性,同时可抑制黑色素的转移,高效清除氧自由基,防止黑色素的产生,同时还原分解已有的黑色素,活化细胞,淡化面部斑点,同时修复由于激素等化学成分对皮肤造成的损伤,从而达到全面快速、标本兼治的效果,使得皮肤美白、滋润保湿、光泽细腻。
附图说明
图1为1-甲基乙内酰脲-2-酰亚胺和传明酸对酪氨酸酶抑制效果比较图。
具体实施方式
为更好的说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明。
实施例1
本发明所述具有美白祛斑作用的护肤品的一种实施例,本实施例所述护肤品为一款美白祛斑霜,所述美白祛斑霜包含以下质量百分含量的成分:
苯乙基间苯二酚0.5%,1-甲基乙内酰脲-2-酰亚胺2%,抗敏修复肽3%,葛根素1%,植酸0.3%,硬脂酸甘油酯2.5%,鲸蜡硬脂基葡糖苷2.5%,肉豆蔻酸异丙酯5%,十六烷基磷酸酯钾盐1%,高级烷基C16-18醇1%,棕榈酸异辛酯5%,维生素E 0.5%,氮酮2%,GTCC(由辛酸/癸酸和甘油酯化而成的高纯度油脂)5%,汉生胶0.3%,尼泊金甲酯0.2%,烟酰胺3%,焦亚硫酸钠0.2%,305(聚丙稀酰胺和脂肪醇聚氧乙烯醚的混合物)1.2%、香精0.2%,余量为水。
一种本实施例美白祛斑霜的制备方法,所述方法包括如下步骤:
将除葛根素、抗敏修复肽、1-甲基乙内酰脲-2-酰亚胺以外的其他原料在去离子水中加热溶解到85℃,混合均匀,然后加入1-甲基乙内酰脲-2-酰亚胺混合均匀,再依次加入抗敏修复肽、葛根素混合均匀,即得所述具有美白祛斑作用的护肤品。
实施例2
本发明所述具有美白祛斑作用的护肤品的一种实施例,本实施例所述护肤品为一款美白祛斑霜,所述美白祛斑霜包含以下质量百分含量的成分:
苯乙基间苯二酚0.05%,1-甲基乙内酰脲-2-酰亚胺0.5%,抗敏修复肽0.5%,葛根素0.5%,植酸0.1%,鲸蜡硬脂基葡糖苷1%,十六烷基磷酸酯钾盐0.5%,硬脂酸甘油酯2.5%,肉豆蔻酸异丙酯5%,,高级烷基C16-18醇1%,棕榈酸异辛酯5%,维生素E 0.5%,氮酮2%,GTCC(由辛酸/癸酸和甘油酯化而成的高纯度油脂)5%,汉生胶0.3%,尼泊金甲酯0.2%,烟酰胺3%,焦亚硫酸钠0.2%,305(聚丙稀酰胺和脂肪醇聚氧乙烯醚的混合物)1.2%、香精0.2%,余量为水。
一种本实施例美白祛斑霜的制备方法,所述方法包括如下步骤:
将除葛根素、抗敏修复肽、1-甲基乙内酰脲-2-酰亚胺以外的其他原料在去离子水中加热溶解到80℃,混合均匀,然后加入1-甲基乙内酰脲-2-酰亚胺混合均匀,再依次加入抗敏修复肽、葛根素混合均匀,即得所述具有美白祛斑作用的护肤品。
实施例3
本发明所述具有美白祛斑作用的护肤品的一种实施例,本实施例所述护肤品为一款美白祛斑霜,所述美白祛斑霜包含以下质量百分含量的成分:
苯乙基间苯二酚0.1%,1-甲基乙内酰脲-2-酰亚胺1%,抗敏修复肽2%,葛根素1.5%,植酸0.5%,十六烷基磷酸酯钾盐1%,鲸蜡硬脂基葡糖苷1.5%,硬脂酸甘油酯3%,肉豆蔻酸异丙酯5%,高级烷基C16-18醇1%,棕榈酸异辛酯5%,维生素E 0.5%,氮酮2%,GTCC(由辛酸/癸酸和甘油酯化而成的高纯度油脂)5%,汉生胶0.3%,尼泊金甲酯0.2%,烟酰胺3%,焦亚硫酸钠0.2%,305(聚丙稀酰胺和脂肪醇聚氧乙烯醚的混合物)1.2%、香精0.2%,余量为水。
一种本实施例美白祛斑霜的制备方法,所述方法包括如下步骤:
将除葛根素、抗敏修复肽、1-甲基乙内酰脲-2-酰亚胺以外的其他原料在去离子水中加热溶解到90℃,混合均匀,然后加入1-甲基乙内酰脲-2-酰亚胺混合均匀,再依次加入抗敏修复肽、葛根素混合均匀,即得所述具有美白祛斑作用的护肤品。
实施例4
本发明所述具有美白祛斑作用的护肤品的一种实施例,本实施例所述护肤品为一款美白祛斑霜,所述美白祛斑霜包含以下质量百分含量的成分:
苯乙基间苯二酚1%,1-甲基乙内酰脲-2-酰亚胺3%,抗敏修复肽4%,葛根素0.5%,植酸0.4%,硬脂酸甘油酯2.5%,肉豆蔻酸异丙酯5%,十六烷基磷酸酯钾盐2.5%,高级烷基C16-18醇1%,棕榈酸异辛酯5%,维生素E 0.5%,氮酮2%,GTCC(由辛酸/癸酸和甘油酯化而成的高纯度油脂)5%,汉生胶0.3%,尼泊金甲酯0.2%,烟酰胺3%,焦亚硫酸钠0.2%,305(聚丙稀酰胺和脂肪醇聚氧乙烯醚的混合物)1.2%、香精0.2%,余量为水。
本实施例美白祛斑霜的制备方法同实施例1
实施例5
本发明所述具有美白祛斑作用的护肤品的一种实施例,本实施例所述护肤品为一款美白祛斑霜,所述美白祛斑霜包含以下质量百分含量的成分:
苯乙基间苯二酚2%,1-甲基乙内酰脲-2-酰亚胺5%,抗敏修复肽5%,葛根素0.5%,植酸0.2%,硬脂酸甘油酯2.5%,鲸蜡硬脂基葡糖苷1%,肉豆蔻酸异丙酯5%,高级烷基C16-18醇1%,棕榈酸异辛酯5%,维生素E 0.5%,氮酮2%,GTCC(由辛酸/癸酸和甘油酯化而成的高纯度油脂)5%,汉生胶0.3%,尼泊金甲酯0.2%,烟酰胺3%,焦亚硫酸钠0.2%,305(聚丙稀酰胺和脂肪醇聚氧乙烯醚的混合物)1.2%、香精0.2%,余量为水。
本实施例美白祛斑霜的制备方法同实施例1。
实施例6
本实施例通过将苯乙基间苯二酚的美白祛斑作用与其他抗氧化美白剂的美白效果进行对比分析,其中,抗氧化IC50值的物理意义为:当达到50%清除率时,单位物质的量的抗氧化剂所清除的DPPH的物质的量,IC50值越高,表示该抗氧化剂的自由基清除能力越强;抑制络氨酸酶IC50值的物理意义为:当抑制率达到50%时的抑制剂浓度,抑制络氨酸酶IC50值可以作为抑制剂抑制能力强弱的对比指标;黑素细胞IC50值的物理意义为:当抑制率达到50%时的抑制剂浓度;美白活性LCR=IC50(细胞毒性,B16V)/IC50(美白效果),IC50(细胞毒性,B16V)值指的是:50%B16V细胞被杀死时的活性物浓度;IC50(美白效果)指的是:络氨酸酶活性抑制率达到50%时,所用到的测试物浓度;B16V指的是黑瘤素细胞,具体相关数据如表1和表2所示:
表1抗氧化美白剂的IC50数据
从表1可以看出,维生素C、VC乙基醚、还原硫辛酸、白藜芦醇、氧化白藜芦醇、四氢姜黄素、己基间二苯酚、光甘草啶等美白剂相比,苯乙基间苯二酚的抗氧化IC50值要大很多,黑素细胞IC50的值小很多,这说明苯乙基间苯二酚的抗氧化和抑制黑素细胞的能力远远强于维生素C、VC乙基醚、还原硫辛酸、白藜芦醇、氧化白藜芦醇、四氢姜黄素、己基间二苯酚、光甘草啶等美白剂,这也进一步说明了苯乙基间苯二酚美白效果比较好。
表2苯乙基间苯二酚和氢醌的美白效果数据对比
化合物 | IC50(细胞毒性,B16V)[μM] | IC50(美白效果)[μM] | LCR |
苯乙基间苯二酚 | 150 | 2.1 | 72 |
氢醌 | 32 | 31 | 1 |
在远低于细胞毒性的浓度下实现美白效果是令人满意的,否则,对酶的抑制会引起细胞毒性。因此,LCR值越大产品越安全,一般来说,LCR>10的产品被视为安全的产品,氢醌的美白效果是细胞毒性产生的,由表2中的数据对比可以看出,苯乙基间苯二酚的LCR值为72,远大于10,更远大于1,苯乙基间苯二酚的是安全的产品。
实施例7
本实施例对1-甲基乙内酰脲-2-酰亚胺的抑制酪氨酸酶活性和抑制黑素小体转移的作用进行研究分析,抑制酪氨酸酶活性的试验方法如下:
1)设置空白溶液、参考溶液、样品溶液、标准溶液,各组溶液的成分如表3所示,除酪氨酸酶外,所有试剂在30℃电热恒温水浴锅内水浴30分钟;
2)按顺序分别加入配置好的1.9ml L-DOPA,2ml缓冲溶液/1-甲基乙内酰脲-2-酰亚胺溶液/传明酸溶液,再加入0.1ml酪氨酸酶溶液;
3)在30℃电热恒温水浴锅内水浴10分钟后,用L5紫外可见分光光度计分别在475nm处测量在测量空白溶液吸光度A,参考溶液的吸光度A0,样品溶液的吸光度B,标准溶液的吸光度B0,并记录数据;
4)按照公式,求出抑制率,分析结果如图1所示:
表3各组溶液的成分
体外酪氨酸酶抑制实验结果:酶浓度为25U/mL,1-甲基乙内酰脲-2-酰亚胺的抑制率达到32%,同等条件下,传明酸抑制率为7.9%。另外,酶浓度为10U/mL,同浓度的1-甲基乙内酰脲-2-酰亚胺和传明酸抑制率分别是28%和10.9%。很明显可以看出,1-甲基乙内酰脲-2-酰亚胺体外酪氨酸酶的抑制效果明显高于常见的美白剂传明酸。
抑制黑素小体转移的分析
体外皮肤黑色素数量检测实验,此实验中曲酸作为阳性对照,每隔一天涂抹本发明所述美白祛斑护肤品,最后用氯仿溶解体外皮肤组织,测量黑色素含量。结果表明实验进行17天后,1-甲基乙内酰脲-2-酰亚胺效果与曲酸一样;而21天后,1-甲基乙内酰脲-2-酰亚胺比曲酸更有效。
另外,人体实验也具有相同的结果,甚至1-甲基乙内酰脲-2-酰亚胺显示的美白效果比曲酸高出30%。
实施例8
本实施例对实施例1~5中所制备得到的美白祛斑霜的美白祛斑效果进行研究分析,测试方法:选30个自愿者参加测试,受试者中分别有雀斑患者5人,妊娠斑患者8人,黄褐斑患者7人,晒斑患者10人,受试者每天使用本发明所述美白祛斑霜,使用一段时间后,分别由18位专业老师进行美白祛斑效果的评价。
结果发现,晒斑患者使用美白祛斑霜半个月后,83.3%患者可以看到脸上的斑有改善现象,使用一个月后,96.7%患者可以看到脸上的斑明显淡化,妊娠斑和黄褐斑患者使用美白祛斑霜半个月后,70%患者可以看到脸上的斑有改善现象,使用一个月后93.3%患者可以看到脸上的斑明显淡化,雀斑患者使用美白祛斑霜一个月后86.7%患者可以看到脸上的斑有改善现象。使用过程中,受试者肤色均提亮不少,而且未出现过敏、刺痛现象。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (10)
1.一种具有美白祛斑作用的护肤品,其特征在于,所述护肤品包括苯乙基间苯二酚、1-甲基乙内酰脲-2-酰亚胺、抗敏修复肽。
2.如权利要求1所述具有美白祛斑作用的护肤品,其特征在于,所述苯乙基间苯二酚在所述护肤品中的质量百分含量为0.05~2%,所述1-甲基乙内酰脲-2-酰亚胺在所述护肤品中的质量百分含量为0.5~5%,所述抗敏修复肽在所述护肤品中的质量百分含量为0.5~5%。
3.如权利要求2所述具有美白祛斑作用的护肤品,其特征在于,所述苯乙基间苯二酚在所述护肤品中的质量百分含量为0.1~1%,所述1-甲基乙内酰脲-2-酰亚胺在所述护肤品中的质量百分含量为1~3%,所述抗敏修复肽在所述护肤品中的质量百分含量为2~4%。
4.如权利要求3所述具有美白祛斑作用的护肤品,其特征在于,所述苯乙基间苯二酚在所述护肤品中的质量百分含量为0.5%,所述1-甲基乙内酰脲-2-酰亚胺在所述护肤品中的质量百分含量为2%,所述抗敏修复肽在所述护肤品中的质量百分含量为3%。
5.如权利要求1~4任一项所述具有美白祛斑作用的护肤品,其特征在于,所述护肤品还包含葛根素,所述葛根素在所述护肤品中的质量百分含量为0.5~1.5%。
6.如权利要求5所述具有美白祛斑作用的护肤品,其特征在于,所述护肤品还包含植酸,所述植酸在所述护肤品中的质量百分含量为0.1~0.5%。
7.如权利要求5所述具有美白祛斑作用的护肤品,其特征在于,所述护肤品还包含表面活性剂,所述表面活性剂包含十六烷基磷酸酯钾盐、鲸蜡硬脂基葡糖苷中的至少一种;
所述表面活性剂包含十六烷基磷酸酯钾盐时,所述十六烷基磷酸酯钾盐在所述护肤品中的质量百分含量为0.5~1.5%;
所述表面活性剂包含鲸蜡硬脂基葡糖苷时,所述鲸蜡硬脂基葡糖苷在所述护肤品中的质量百分含量为1~3%。
8.如权利要求6或7所述具有美白祛斑作用的护肤品,其特征在于,所述护肤品还包含抗氧化剂、润湿剂、促渗剂、增稠稳定剂、杀菌防腐剂、乳化剂中的至少一种。
9.如权利要求8所述具有美白祛斑作用的护肤品,其特征在于,所述抗氧化剂为维生素E、焦亚硫酸钠中的至少一种,所述润湿剂为肉豆蔻酸异丙酯,所述促渗剂为氮酮,所述增稠稳定剂为汉生胶,所述杀菌防腐剂为尼伯金甲酯,所述乳化剂为硬脂酸甘油酯。
10.一种如权利要求1~9任一所述具有美白祛斑作用的护肤品的制备方法,其特征在于,所述方法包括如下步骤:
将除葛根素、抗敏修复肽、1-甲基乙内酰脲-2-酰亚胺以外的其他原料在去离子水中加热溶解到80~90℃,混合均匀,然后加入1-甲基乙内酰脲-2-酰亚胺混合均匀,再依次加入抗敏修复肽、葛根素混合均匀,即得所述具有美白祛斑作用的护肤品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610944379.0A CN106333869B (zh) | 2016-11-02 | 2016-11-02 | 一种具有美白祛斑作用的护肤品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610944379.0A CN106333869B (zh) | 2016-11-02 | 2016-11-02 | 一种具有美白祛斑作用的护肤品及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106333869A true CN106333869A (zh) | 2017-01-18 |
CN106333869B CN106333869B (zh) | 2020-05-19 |
Family
ID=57840600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610944379.0A Active CN106333869B (zh) | 2016-11-02 | 2016-11-02 | 一种具有美白祛斑作用的护肤品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106333869B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108096095A (zh) * | 2017-12-27 | 2018-06-01 | 珠海伊斯佳科技股份有限公司 | 一种复合美白和舒缓皮肤刺激功能的组合物及其应用 |
CN108186388A (zh) * | 2018-02-08 | 2018-06-22 | 广州美尔生物科技有限公司 | 一种祛斑护肤品及其制备方法 |
CN108210384A (zh) * | 2018-01-04 | 2018-06-29 | 广州雅纯化妆品制造有限公司 | 一种美白祛斑护肤品及其制备方法 |
CN108434057A (zh) * | 2018-05-29 | 2018-08-24 | 广州美尔生物科技有限公司 | 一种温和祛斑组合物及其制备方法 |
CN108478498A (zh) * | 2018-06-28 | 2018-09-04 | 广东格烯生物科技股份有限公司 | 一种改善皮肤肤色的组合物及其制备方法和应用 |
CN110897995A (zh) * | 2019-12-13 | 2020-03-24 | 深圳市琉璃光生物科技有限公司 | 一种美白膏霜及其制备方法 |
CN114028296A (zh) * | 2021-12-13 | 2022-02-11 | 上海宜侬生物科技有限公司 | 一个多维度修护皮肤敏感的化妆品成分与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080069784A1 (en) * | 2006-06-30 | 2008-03-20 | Millikin Cheri L | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
CN103025310A (zh) * | 2010-05-25 | 2013-04-03 | 西姆莱斯有限公司 | 作为皮肤和/或毛发美白活性物的氨基甲酸环己酯化合物 |
CN104023737A (zh) * | 2011-11-04 | 2014-09-03 | 利普泰股份公司 | 抑制被激活受体的肽及其在化妆品组合物或药物组合物中的用途 |
-
2016
- 2016-11-02 CN CN201610944379.0A patent/CN106333869B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080069784A1 (en) * | 2006-06-30 | 2008-03-20 | Millikin Cheri L | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
CN103025310A (zh) * | 2010-05-25 | 2013-04-03 | 西姆莱斯有限公司 | 作为皮肤和/或毛发美白活性物的氨基甲酸环己酯化合物 |
CN104023737A (zh) * | 2011-11-04 | 2014-09-03 | 利普泰股份公司 | 抑制被激活受体的肽及其在化妆品组合物或药物组合物中的用途 |
Non-Patent Citations (2)
Title |
---|
孙宝国: "《日用化工辞典》", 30 June 2002, 化学工业出版社 * |
宋丽雅 等: "《化妆品植物功效添加剂的研究与开发》", 30 September 2011, 中国轻工业出版社 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108096095A (zh) * | 2017-12-27 | 2018-06-01 | 珠海伊斯佳科技股份有限公司 | 一种复合美白和舒缓皮肤刺激功能的组合物及其应用 |
CN108210384A (zh) * | 2018-01-04 | 2018-06-29 | 广州雅纯化妆品制造有限公司 | 一种美白祛斑护肤品及其制备方法 |
CN108186388A (zh) * | 2018-02-08 | 2018-06-22 | 广州美尔生物科技有限公司 | 一种祛斑护肤品及其制备方法 |
CN108434057A (zh) * | 2018-05-29 | 2018-08-24 | 广州美尔生物科技有限公司 | 一种温和祛斑组合物及其制备方法 |
CN108434057B (zh) * | 2018-05-29 | 2020-11-10 | 广州美尔生物科技有限公司 | 一种温和祛斑组合物及其制备方法 |
CN108478498A (zh) * | 2018-06-28 | 2018-09-04 | 广东格烯生物科技股份有限公司 | 一种改善皮肤肤色的组合物及其制备方法和应用 |
CN110897995A (zh) * | 2019-12-13 | 2020-03-24 | 深圳市琉璃光生物科技有限公司 | 一种美白膏霜及其制备方法 |
CN114028296A (zh) * | 2021-12-13 | 2022-02-11 | 上海宜侬生物科技有限公司 | 一个多维度修护皮肤敏感的化妆品成分与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106333869B (zh) | 2020-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106333869A (zh) | 一种具有美白祛斑作用的护肤品及其制备方法 | |
Wang et al. | Red raspberry extract protects the skin against UVB‐induced damage with antioxidative and anti‐inflammatory properties | |
US20200085897A1 (en) | Extract of Aerial Parts of Maca Rich in Polyphenols and Composition Comprising Same | |
CN103989589B (zh) | 含有香豆雌酚或包含香豆雌酚的豆提取物的、用于皮肤护理的化妆品组合物 | |
KR101972071B1 (ko) | 피부톤 개선 또는 피부 탄력 증진용 화장료 조성물 | |
TWI466686B (zh) | Whitening agents, anti-aging agents and antioxidants, and whitening endermic agents, anti-aging and anti-skin external oxidation method for producing a skin external preparation of | |
CN106137812A (zh) | 龙胆提取物及其制备方法和用途 | |
CN104490628A (zh) | 一种天然美白滋养浴后乳液及其制备方法 | |
CN105267268B (zh) | 人参叶提取物制造方法及包含其为有效成分的化妆品组合物 | |
EP3090781A1 (en) | Anti-age composition with plant extracts | |
KR101711002B1 (ko) | 인삼잎추출물 제조방법 및 이를 유효성분으로 함유하는 화장료 조성물 | |
KR101026879B1 (ko) | 피부주름개선용 화장료 조성물의 제조방법 | |
KR101131574B1 (ko) | 피부 미백용 조성물 | |
KR102063686B1 (ko) | 콩뿌리 추출물을 함유하는 피부 외용제 조성물 | |
KR20110015171A (ko) | 연산호류 추출물 및 그것의 용도 | |
KR102476670B1 (ko) | 혼합 추출물을 포함하는 화장료 조성물 | |
KR101402193B1 (ko) | 아위버섯 자실체 추출물 또는 아위버섯 균사체 추출물 또는 아위버섯 균사체 배양액을 함유하는 피부 미백용 화장료 조성물 | |
CN107427453A (zh) | 五味子果实的肽和糖苷提取物及其对皮肤神经系统反应的改善作用 | |
BR112020017365A2 (pt) | Extrato de tetraselmis | |
JP2012162487A (ja) | 美白剤、抗老化剤及び皮膚化粧料 | |
KR20090097550A (ko) | 슈잔드린 및 이 추출물을 유효성분으로 함유하는 화장료조성물 | |
KR20140126891A (ko) | 진세노사이드 Rf를 함유하는 피부 외용제 조성물 | |
KR101458496B1 (ko) | 아위버섯 자실체 추출물 또는 아위버섯 균사체 추출물 또는 아위버섯 균사체 배양액을 함유하는 항염용 피부 외용제 조성물 | |
KR101909533B1 (ko) | 진세노사이드 f1을 함유하는 피부 외용제 조성물 | |
JP2009102378A (ja) | 幹細胞因子の産生・放出の抑制による掻痒、肌荒れ、敏感肌及び美白用薬剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231129 Address after: 510000 Room 305, building B3, mawulianhe Industrial Zone, Huangyuan Road, Baiyun District, Guangzhou City, Guangdong Province Patentee after: GUANGZHOU BAFEORII CHEMICAL CO.,LTD. Address before: Building C, 3rd Floor, No. 13 Kexing West Road, Guangzhou Private Science and Technology Park, No. 1633 Beitai Road, Baiyun District, Guangzhou City, Guangdong Province, 510445 Patentee before: GUANGZHOU MEIER BIOTECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right |